Improve Oversight Of Hospital Discount Drug Program, Watchdogs Say
As participation in the federal 340B drug discount program has quickly expanded, officials told lawmakers at a House hearing that new legislation may be necessary to make sure that benefits go to eligible providers and patients.
Federal Watchdogs Seek Better Oversight Of 340B Drug Discounts
Federal officials told lawmakers Tuesday that the 340B drug discount program needs greater transparency and more clarity about which providers and patients should be eligible. Such changes will improve oversight of a program that has seen a stark rise in its participation over the past decade, they said. (Johnson, 3/24)
New Rules Seen For Drug Discount Program
The rapid expansion of the federal 340B discount drug program may require new legislation to make sure that its benefits reach the intended population, the neediest Americans, lawmakers said Tuesday. Rep. Larry Bucshon, R-Ind., was among those who raised concerns at a House Energy and Commerce subcommittee hearing about the lack of firm directives to hospitals about how savings from the program should be used. Hospitals, clinics and other health agencies enrolled in the program saved about $3.8 billion in 2013 by acquiring steeply discounted drugs, according to the Health Resources and Services Administration. (Young, 3/24)